Gemcitabine‐based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non‐Hodgkin's lymphoma

No abstract is available for this paper.

• Publication year

  2009

• Venue

  American journal of hematology/oncology

• Publication date

  2009-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ajh.21436PMID 19484737
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adjuvant Therapy Reduces Rate of Dissemination but Shortens Survival Thereafter.

  2015cited by this paper
• Nomenclature for factors of the HLA system.

  2011cited by this paper
• Successful treatment of cyclic thrombocytopenia with thrombopoietin‐mimetic agents: A report of two patients

  2009cited by this paper
• Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia.

  2009cited by this paper
• Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP.

  2009cited by this paper
• Late relapse of acute myeloid leukemia with mutated NPM1 after eight years: evidence of NPM1 mutation stability

  2009cited by this paper
• Circulating endothelial cells (CECs) and progenitors (CEPs) in severe haemophiliacs with different clinical phenotype

  2009cited by this paper
• Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial.

  2008cited by this paper
• Stochastic modeling of human RBC alloimmunization: evidence for a distinct population of immunologic responders.

  2008cited by this paper
• Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes.

  2008cited by this paper
• Alloantibody responses in multiply transfused sickle cell patients.

  2008cited by this paper
• Twenty years of follow‐up among survivors of childhood and young adult acute myeloid leukemia

  2008cited by this paper
• MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.

  2008cited by this paper
• Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms

  2008cited by this paper
• Effects of simulated altitude (normobaric hypoxia) on cardiorespiratory parameters and circulating endothelial precursors in healthy subjects

  2007cited by this paper
• Clinical predictors of alloimmunization after red blood cell transfusion

  2007cited by this paper
• Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.

  2007cited by this paper
• Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.

  2007cited by this paper
• Relapsed acute myelogenous leukemia occurring after 18 years with recurrent novel chromosomal abnormality t(18;22)(q23;q11.2).

  2007cited by this paper
• Correlations of JAK2-V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders.

  2007cited by this paper
• Flow cytometric evaluation of circulating endothelial cells: A new protocol for identifying endothelial cells at several stages of differentiation

  2007cited by this paper
• Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (>5 years)

  2007cited by this paper
• Abcb7, the gene responsible for X-linked sideroblastic anemia with ataxia, is essential for hematopoiesis.

  2007cited by this paper
• Relative immunogenicity of Fya and K antigens in a Caucasian population, based on HLA class II restriction analysis

  2006cited by this paper
• Comparison of the performance of microtube column systems and solid‐phase systems and the tube low‐ionic‐strength solution additive indirect antiglobulin test in the detection of red cell alloantibodies

  2006cited by this paper
• Late Relapses in Acute Promyelocytic Leukaemia

  2006cited by this paper
• Interruption of tumor dormancy by a transient angiogenic burst within the tumor microenvironment.

  2006cited by this paper
• Detection of circulating endothelial cells and endothelial progenitor cells by flow cytometry

  2006cited by this paper
• Changes in serum cardiac troponins following a 21-km run in junior male runners.

  2006cited by this paper
• HLA‐DRB1 polymorphism is associated with Kell immunisation

  2006cited by this paper
• Endothelial colony forming capacity is related to C-reactive protein levels in healthy subjects.

  2006cited by this paper
• Detection of the JAK2 V617F mutation by LightCycler PCR and probe dissociation analysis.

  2006cited by this paper
• Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma

  2005cited by this paper
• How to interpret and pursue an abnormal complete blood cell count in adults.

  2005cited by this paper
• JAK2V617F mutation in essential thrombocythaemia: clinical associations and long‐term prognostic relevance

  2005cited by this paper
• Effects of Exercise and Ischemia on Mobilization and Functional Activation of Blood-Derived Progenitor Cells in Patients With Ischemic Syndromes: Results of 3 Randomized Studies

  2005cited by this paper
• High‐Altitude trekking in the Himalayas increases the activity of circulating endothelial cells

  2005cited by this paper
• HLA‐DRB1 alleles and Jka immunization

  2005cited by this paper
• Circulating endothelial (progenitor) cells reflect the state of the endothelium: vascular injury, repair and neovascularization

  2005cited by this paper
• Detection of circulating endothelial cells and endothelial progenitor cells by flow cytometry

  2005cited by this paper
• Mitochondrial myopathy and sideroblastic anemia

  2004cited by this paper
• Historical keywords: trial.

  2004cited by this paper
• Missense mutation in pseudouridine synthase 1 (PUS1) causes mitochondrial myopathy and sideroblastic anemia (MLASA).

  2004cited by this paper
• Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B‐cell non‐Hodgkin lymphoma

  2004cited by this paper
• Improving second-line therapy in aggressive non-Hodgkin's lymphoma.

  2004influential reference
• Cis-dichlorodiammineplatinum (Cis-platinum) and etoposide (VP-16) in malignant lymphoma — an effective salvage regimen

  2004influential reference
• Exercise acutely increases circulating endothelial progenitor cells and monocyte-/macrophage-derived angiogenic cells.

  2004cited by this paper
• Autoantibody formation after alloimmunization: are blood tranfusions a risk factor for autoimmune hemolytic anemia?

  2004cited by this paper
• Endothelial progenitor cells: mobilization, differentiation, and homing.

  2003cited by this paper
• Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM‐P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non‐Hodgkin's lymphoma

  2003cited by this paper
• Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis.

  2003cited by this paper
• WBC reduction of RBC transfusions is associated with a decreased incidence of RBC alloimmunization

  2003cited by this paper
• Late relapses evolve from slow-responding subclones in t(12;21)-positive acute lymphoblastic leukemia: evidence for the persistence of a preleukemic clone.

  2003cited by this paper
• The World Health Organization (WHO) classification of the myeloid neoplasms.

  2002cited by this paper
• Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions

  2002cited by this paper
• Predicting the effect of transfusing only phenotype‐matched RBCs to patients with sickle cell disease: theoretical and practical implications

  2002cited by this paper
• The genetics of inherited sideroblastic anemias.

  2002cited by this paper
• Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management.

  2001cited by this paper
• Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS.

  2001cited by this paper
• Cyclic immune thrombocytopenia responsive to thrombopoietic growth factor therapy

  2001cited by this paper
• Prospective RBC phenotype matching in a stroke‐prevention trial in sickle cell anemia: a multicenter transfusion trial

  2001cited by this paper
• Morbidity and mortality in adults with idiopathic thrombocytopenic purpura.

  2001cited by this paper
• Thrombocytopenia caused by the development of antibodies to thrombopoietin.

  2001cited by this paper
• Plasma levels of cardiac troponin I after prolonged strenuous endurance exercise.

  2001cited by this paper
• Diagnosis of essential thrombocythemia at platelet counts between 400 and 600x10(9)/L. Gruppo Italiano Malattie Mieloproliferative Croniche(GIMMC).

  2000cited by this paper
• Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH.

  2000cited by this paper
• Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly asian descent.

  2000cited by this paper
• The gene mutated in thiamine-responsive anaemia with diabetes and deafness (TRMA) encodes a functional thiamine transporter

  1999cited by this paper
• Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma.

  1999cited by this paper
• HLA Class I Homozygosity Accelerates Disease Progression in Human Immunodeficiency Virus Type 1 Infection

  1999cited by this paper
• Mutation of a Putative Mitochondrial Iron Transporter Gene (ABC7) in X-Linked Sideroblastic Anemia and Ataxia (XLSA/A)

  1999cited by this paper
• Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma.

  1999influential reference
• Erythrocyte autoantibodies in paediatric patients with sickle cell disease receiving transfusion therapy: frequency, characteristics and significance

  1999cited by this paper
• Should a platelet limit of 600 × 109/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages

  1998cited by this paper
• Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography.

  1998cited by this paper
• Endothelial cells in physiology and in the pathophysiology of vascular disorders.

  1998cited by this paper
• Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment.

  1997cited by this paper
• Nomenclature for Factors of the HLA System, 1996

  1997cited by this paper
• Long‐term follow‐up of cancer and leukemia group B studies in acute myeloid leukemia

  1997cited by this paper
• Synergistic interaction between cisplatin and gemcitabine in vitro.

  1996influential reference
• The effects of blood transfusion on cytokine production by TH1 and TH2 lymphocytes in the mouse.

  1996cited by this paper
• Cytokine secretion after allogeneic or autologous blood transfusion.

  1995cited by this paper
• Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia.

  1995cited by this paper
• X-linked sideroblastic anemia: identification of the mutation in the erythroid-specific delta-aminolevulinate synthase gene (ALAS2) in the original family described by Cooley.

  1994cited by this paper
• Long‐term safety of treatment with recombinant human granulocyte colony‐stimulating factor (r‐metHuG‐CSF) in patients with severe congenital neutropenias

  1994cited by this paper
• Antigen‐matched donor blood in the transfusion management of patients with sickle cell disease

  1994cited by this paper
• Efficient typing of the HLA-B locus using the PCR and immobilized oligonucleotide probes

  1994cited by this paper
• ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.

  1994cited by this paper
• Clinical exercise testing. A review of personal and community practice experience.

  1994cited by this paper
• Management of patients with sickle cell disease.

  1992cited by this paper
• Enzymatic defect in "X-linked" sideroblastic anemia: molecular evidence for erythroid delta-aminolevulinate synthase deficiency.

  1992cited by this paper
• Trisomy 4 in acute myeloid leukaemia.

  1991cited by this paper
• [Sideroblastic anemias].

  1991cited by this paper
• Transfusion and alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease.

  1990cited by this paper
• Trisomy 4: a specific karyotype anomaly in primary and secondary acute myeloid leukemia.

  1990cited by this paper
• Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood.

  1990cited by this paper
• Treatment of cyclic neutropenia with granulocyte colony-stimulating factor.

  1989cited by this paper
• Decreased Leukocyte Ferrochelatase Activity in Erythropoietic Protoporphyria

  1989cited by this paper
• Variability in rates of alloimmunization in different groups of children with sickle cell disease: effect of ethnic background.

  1989cited by this paper
• Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP).

  1988influential reference

• Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma.

  2010cites this paper